Stocktoria
Century Therapeutics, Inc. IPSC
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-17
Century Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -15.8% | -2096.5% | -6556.9% | -2574.2% | — |
| Net margin | -8.8% | -1920.9% | -6115.1% | -2518.4% | — |
| FCF margin | -95.9% | -1673.8% | -4567.5% | -318.4% | — |
| Return on assets | -4.3% | -35.8% | -37.9% | -26.9% | -21.9% |
| Return on equity | -6.0% | -78.4% | -74.0% | -43.2% | -24.2% |
| Debt / equity | — | — | — | 0.03× | 0.03× |
| Current ratio | 5.97 | 1.50 | 9.92 | 10.72 | 14.57 |
| Revenue growth | 1556.8% | 194.8% | -57.0% | — | — |
Source: SEC EDGAR filings · CIK 0001850119 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.